Fund balancing drive sparks controversy in Germany
This article was originally published in Clinica
Draft proposals by German health minister Ulla Schmidt to reform the financing of the statutory health insurance funds have come under sustained fire from the companies' sickness Fund (BKK). The confederation of German employers' associations, opposition parties and doctors' associations have also weighed in with their criticisms.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.
How do notified bodies ensure that their personnel, and the teams they allocate for conformity assessment of medical devices, have the precise knowledge and expertise needed? A new EU document gives guidance on this.